These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology of glucocorticoids in rheumatoid arthritis. Spies CM; Bijlsma JW; Burmester GR; Buttgereit F Curr Opin Pharmacol; 2010 Jun; 10(3):302-7. PubMed ID: 20202903 [TBL] [Abstract][Full Text] [Related]
7. Are modified-release corticosteroids good therapeutic options for patients with RA? Katz SJ; Russell AS Nat Clin Pract Rheumatol; 2008 Jun; 4(6):290-1. PubMed ID: 18431370 [TBL] [Abstract][Full Text] [Related]
8. Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis. Ursini F; Naty S; Bruno C; Grembiale RD Rev Recent Clin Trials; 2017; 12(2):124-128. PubMed ID: 28356031 [TBL] [Abstract][Full Text] [Related]
10. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974 [TBL] [Abstract][Full Text] [Related]
11. Delayed-release prednisone - a new approach to an old therapy. Buttgereit F; Gibofsky A Expert Opin Pharmacother; 2013 Jun; 14(8):1097-106. PubMed ID: 23594208 [TBL] [Abstract][Full Text] [Related]
12. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. Alten R; Döring G; Cutolo M; Gromnica-Ihle E; Witte S; Straub R; Buttgereit F J Rheumatol; 2010 Oct; 37(10):2025-31. PubMed ID: 20682671 [TBL] [Abstract][Full Text] [Related]
13. How should impaired morning function in rheumatoid arthritis be treated? Buttgereit F Scand J Rheumatol Suppl; 2011; 125():28-39. PubMed ID: 21529308 [TBL] [Abstract][Full Text] [Related]
14. Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. Kirwan JR; Buttgereit F Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv14-20. PubMed ID: 22685271 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Pincus T; Swearingen CJ; Luta G; Sokka T Ann Rheum Dis; 2009 Nov; 68(11):1715-20. PubMed ID: 19074913 [TBL] [Abstract][Full Text] [Related]
16. Modified-release prednisone: in patients with rheumatoid arthritis. Henness S; Yang LP Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648 [TBL] [Abstract][Full Text] [Related]
17. Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study. Dikranian AH; Mallay R; Marshall M; Francis-Sedlak M; Holt RJ Rheumatol Ther; 2017 Dec; 4(2):363-374. PubMed ID: 28819927 [TBL] [Abstract][Full Text] [Related]
18. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Pincus T; Cutolo M Neuroimmunomodulation; 2015; 22(1-2):46-50. PubMed ID: 25227901 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Cutolo M; Iaccarino L; Doria A; Govoni M; Sulli A; Marcassa C Clin Exp Rheumatol; 2013; 31(4):498-505. PubMed ID: 23415134 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]